November 2, 2021 5:09pm

The sector started with a big downslide and ultimately drives to a quirky upside while sentiment is slippery and lackluster with share pricing risk orientation

Pre-open indication results: 4 HITs and 1 MISS

Earnings results: MiMedx (MDXG), Sage Therapeutics (SAGE), Ultragenyx Pharmaceuticals (RARE), Voyager Therapeutics (VYGR) and Regenxbio (RGNX) <read more>

My version of the session’s “indications” is about what you need to know; it’s what did happen after the opening, mid-day and to the close

An objective, fact and numbers-based narrative – check the numbers!

The Dow closed UP +138.79 points (+0.39%); the S&P closed UP +16.98 points (+0.37%) while the Nasdaq closed UP +53.69 points (+0.34%)

 

Henry’omics:

All three major U.S. stock indexes hit new intraday highs after having closed at records during Monday’s session.

The Fed’s about to indicate it’s going to pull back on some stimulus with its two-day meeting beginning today.

 

Earnings results:

Sage Therapeutics (SAGE) had a net loss of -$130.2 m, a negative loss per share of -$2.21, a cash position of $121.5 M with low revenue of 1.4 m,

Voyager Therapeutics (VYGR) had a net loss of -$25.1 m, a negative loss per share of -$0.67, a cash position of $1.8 B with low revenue of $1.5 m,

Ultragenyx Pharmaceuticals (RARE) had a net loss of -$25.1 m, a negative loss per share of -$0.67, a cash position of $1.8 B with low revenue of $1.5 m, with $81.6 m in revenue, a decrease from Q3/20

Regenxbio (RGNX) had a net loss of -$58.4 m, a negative loss per share of -$1.37, a cash position of $553.6 m with low revenue of $1.5 m, with $30.7 m in revenue – a decrease from Q3/20,

MiMedex (MDXG) had a net loss of -$2.3 m, a negative -$0.04 loss per share, a cash position of $90.6 m, a dramtic decrease (from -$19.4 m) in LPS from Q3/20, a decrease in revenue, issue a $350 shelf existing.

 

Note: Biostage (BSTG) was down -$0.10 to $3.00 with 200 shares traded, flat again $0.00 on Monday with 80 shares traded to $3.10 after Friday’s 162 shares traded, Thursday’s 95 shares traded and last Wednesday’s move from -$0.40 with 216 shares traded until the “pump” was turned-on with 1,676 shares traded to close +$0.10 – where is the SEC?

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what’s happening …

  • Tuesday opened negative at 10/22, 2 flats and 1 acquired, stayed negative at the mid-day at 16/17, 1 flat and 1 acquired, ending with a positive close of 24/8, 2 flats and 1 acquired;
  • Monday opened positive at 31/2, 1 flat and 1 acquired, stayed positive at the mid-day at 30/1, 3 flats and 1 acquired, ending with a positive close of 29/3, 2 flats and 1 acquired;

 

RegMed Investors’ (RMi) pre-open: “time to show their cards in earnings from the sector as the downside market risks take its toll.” … https://www.regmedinvestors.com/articles/12164

 

Pre-open indication results: 4 Hit: <SELL: Biostage (BSTG -$0.10); Maintaining SELL into Strength: Intellia Therapeutics (NTLA -$0.83), ReNeuron (RENE.L -$4.50), Sage Therapeutics (SAGE +$1.20)> and 1 MISS <Verastem (VSTM +$0.07)>

 

Key Metric - volume:

Sector volume LOW with 7 of the 24-upside having higher than the 3-month average volume with LOW volume of 2 of 8-downside having higher than the 3-month average volume;

Upside Volume:

  • Sangamo Therapeutics (SGMO) +$0.11 with 3.36 m shares traded,
  • Sage Therapeutics (SAGE) +$1.20 with 1.423 m shares traded,

 

There are clear winners and losers

Jumping with share pricing momentum (10 of 24):

  • uniQure NV (QURE +$1.41 after Monday’s +$1.23),
  • Alnylam Pharmaceuticals (ALNY +$1.29 after Monday’s +$6.80),
  • Sage Therapeutics (SAGE +$1.20 after Monday’s +$2.01),
  • Vericel (VCEL +$1.12 after Monday’s -$0.18),
  • BioLife Solutions (BLFS +$1.06),
  • Cellectis SA (CLLS +$0.83),
  • bluebird bio (BLUE +$0.568),
  • Regenxbio (RGNX +$0.43),
  • CRISPR Therapeutics (CRSP +$0.38 after Monday’s +$4.13),
  • Chinook Therapeutics (KDNY +$0.27),

Hammered in today’s market (8 of 8):

  • ReNeuron (RENE.L -$4.50 after Monday’s flat),
  • Ultragenyx (RARE -$1.15 after Monday’s +$2.06),
  • Intellia Therapeutics (NTLA -$0.83 after Monday’s +$3.53),
  • Editas Medicine (EDIT -$0.39 after Monday’s +$1.89),
  • Biostage (BSTG -$0.10 after Monday’s flat),
  • Mesoblast (MESO -$0.06),
  • Bellicum Pharmaceuticals (BLCM -$0.03),
  • Ionis Pharmaceuticals (IONS -$0.03 after Monday’s +$1.13),

Closing Flat:

  • 2 – Pluristem (PSTI), Caladrius Biosciences (CLBS) and 1 - Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB closed up +0.64% and XBI closed up +1.29%
  • Monday, the IBB closed up +1.27% and XBI closed up +3.79%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was down -0.38 points or -2.32% at 16.03
  • Monday was up +0.15 points or +0.92% at 16.41

 

November, the second month of Q4/21:

Tuesday closed positive with 24 incliners, 8 decliners, 2 flats and 1 acquired

Monday (11/1) closed positive with 29 incliners, 3 decliners, 2 flats and 1 acquired

 

The BOTTOM LINE:  Reiterating, “Don't let earnings week take advantage of you” … because it will!

We are seeing to date, seven (7) net losses <uniQure (QURE), Alnylam Pharmaceuticals (ALNY), Regenxbio (RGNX), Sage Therapeutics SAGE), Ultragenyx Pharmaceuticals (RARE), MiMedx (MDXG) and Voyager therapeutics (VYGR)> earning’s releases that initiated Q3 earnings reporting season and beginning the tug-of-war between share pricing that is softer than usual and the usual LPS (loss-per-share) to be less than estimates and expectations.

The stem, cell and gene therapy earnings coming with Sangamo therapeutics (SGMO) and Intellia Therapeutics (NTLA), Caladrius Biosciences (CLBS) on 11/4, Cellectis SA (CLLS) on 11/5, Editas Medicine (EDIT) on 11/8, Vericel (VCEL) and Applied Genetic Technologies (AGTC) on 11/9, Athersys (ATHX) and Brainstorm Cell Therapeutics (BCLI) coming 11/15 (to date).

Reiterating, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme low volume moves in either direction, as share pricing risk stimulates their susceptibility!”

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.